barzolvolimab

TypeInjection StagePhase 2 Latest updateMay 6, 2026Phase 2 main data collected

What stands out

New approach in eczema

Injection every 4 weeks in trials
Binds to KIT (c-Kit), a growth switch involved in mast-cell development and function

Derived from FDA substance registry · NCT06727552 · UniProt P10721 ·

11 US eczema labels

(Cibinqo, Eucrisa, Adquey, Dupixent, Ebglyss, Nemluvio, Zoryve, Opzelura, Vtama, Adbry, Rinvoq)

· This is a summary of public records for informational purposes only. It is not medical advice.

History

Earliest recorded event: Dec 18, 2024. This timeline shows events collected by Eczema Radar and may not include the treatment’s full history. Study details reflect the latest registry record available here.

May 6, 2026Phase 2 main data collectedA Study of Barzolvolimab in Patients With Atopic Dermatitis ClinicalTrials.gov NCT06727552
Dec 18, 2024Phase 2 trial startedA Study of Barzolvolimab in Patients With Atopic Dermatitis ClinicalTrials.gov NCT06727552

Sources

Trials

NCT06727552